Health Care • Biotechnology: Pharmaceutical Preparations
$50.53 ▼ -0.78
(-1.52%)
MKT CAP: $958.5M • VOL: 136.1K
52W L $25 52W H $53
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$42
MEDIAN
$57
MEAN
$58
HIGH
$69
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RIGL TAPE
RIGL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $61.14 | $58.11 | 2025-02-14 | $45.98 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $63.67 | $59.63 | 2025-02-06 | $47.50 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $57.60 | $55.58 | 2025-01-29 | $48.51 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $51.54 | — | 2025-01-17 | $49.52 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $44.47 | $48.00 | 2025-01-09 | $44.97 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $60.13 | $52.55 | 2024-12-18 | $43.96 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $49.01 | $51.04 | 2024-12-04 | $46.99 | -4.3% | 48% | C |